Patents by Inventor Stephen Danko

Stephen Danko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical formulations for IGF/IGFBP
    Publication number: 20030087806
    Abstract: New pharmaceutical formulations for IGF/IGFBP complex are disclosed. IGF/IGFBP complex, preferably rhIGF-I/IGFBP-3 complex is formulated with bulking agents and optionally buffer salts, but without added osmolyte salts. Also disclosed are lyophilized formulations for IGF/IGFBP complex.
    Type: Application
    Filed: August 20, 2002
    Publication date: May 8, 2003
    Applicant: Insmed Inc.
    Inventors: Stephen Danko, David Passmore, Yasushi Ogawa
  • Pharmaceutical formulations for IGF/IGFBP
    Patent number: 6436897
    Abstract: New pharmaceutical formulations for IGF/IGFBP complex are disclosed. IGF/IGFBP complex, preferably rhIGF-I/IGFBP-3 complex is formulated with bulking agents and optionally buffer salts, but without added osmolyte salts. Also disclosed are lyophilized formulations for IGF/IGFBP complex.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: August 20, 2002
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: Stephen Danko, David Passmore, Yasushi Ogawa
  • Insulin-like growth factor binding protein variants
    Patent number: 6417330
    Abstract: The invention relates to variants of native insulin-like growth factor binding protein 3 (IGFBP-3). Variant IGFBP-3s are disclosed which are modified to be resistant to hydrolysis. Also disclosed are variant IGFBP-3s where the nuclear localization signal (NLS) in native IGFBP-3 is altered. Additionally, amino-terminally extended IGFBP-3s are disclosed which include a variety of N-terminal extensions, including peptide and nucleotide binding domains, specific binding members such as ligand binding domains from receptors or antigen binding domains from immunoglobins, and peptide and protein hormones and growth factors. N-terminally extended IGFBP-3s may comprise hydrolysis-resistant or NLS variant IGFBP-3s.
    Type: Grant
    Filed: May 27, 1999
    Date of Patent: July 9, 2002
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: Desmond Mascarenhas, David Passmore, Stephen Danko
  • Insulin-like growth factor binding protein variants
    Publication number: 20020072589
    Abstract: The invention relates to variants of native insulin-like growth factor binding protein 3 (IGFBP-3). Variant IGFBP-3s are disclosed which are modified to be resistant to hydrolysis. Also disclosed are variant IGFBP-3s where the nuclear localization signal (NLS) in native IGFBP-3 is altered. Additionally, amino-terminally extended IGFBP-3s are disclosed which include a variety of N-terminal extensions, including peptide and nucleotide binding domains, specific binding members such as ligand binding domains from receptors or antigen binding domains from immunoglobins, and peptide and protein hormones and growth factors. N-terminally extended IGFBP-3s may comprise hydrolysis-resistant or NLS variant IGFBP-3s.
    Type: Application
    Filed: November 13, 2001
    Publication date: June 13, 2002
    Applicant: Celtrix Pharmaceuticals, Inc.
    Inventors: Desmond Mascarenhas, David Passmore, Stephen Danko
  • PHARMACEUTICAL FORMULATIONS FOR IGF/IGFBP
    Publication number: 20020004478
    Abstract: New pharmaceutical formulations for IGF/IGFBP complex are disclosed. IGF/IGFBP complex, preferably rhIGF-I/IGFBP-3 complex is formulated with bulking agents and optionally buffer salts, but without added osmolyte salts. Also disclosed are lyophilized formulations for IGF/IGFBP complex.
    Type: Application
    Filed: June 1, 1998
    Publication date: January 10, 2002
    Inventors: STEPHEN DANKO, DAVID PASSMORE, YASUSHI OGAWA